Skip navigation

Signatera™ for circulating tumor DNA (ctDNA) monitoring in skin cancer


Changing the management of cancer with circulating tumor DNA testing.

Contact us

Know sooner

Signatera is a personalized, tumor-informed assay with the power to give you earlier, clearer insight into residual disease status. By detecting and monitoring the dynamics of ctDNA, Signatera can help optimize treatment plans in skin cancers such as melanoma and merkel cell carcinoma.1-4

Treatment response monitoring for those living with skin cancer

Jeffrey was diagnosed with metastatic melanoma after he discovered a growth under his arm. His oncologist used Signatera to understand if his immunotherapy was working. Watch Jeffrey’s story to learn how Signatera helped him look forward to the future again.

After Steven was diagnosed with metastatic melanoma, his oncologist ordered Signatera to track his ctDNA levels over time. Signatera helped support that he had no evidence of disease. Watch Steven’s story to learn how Signatera helped him rediscover hope.

Support for critical decisions across the immunotherapy journey

IO Brochure

Discover how Signatera can inform important health care decisions for people receiving immunotherapy1


Read how Signatera combined with standard imaging can predict immunotherapy response as early as 6 weeks into treatment.

Melanoma SignaCase

Learn how Signatera can help identify progression in the absence of clear imaging results1


Enroll in a clinical trial designed to help understand how Signatera can help guide immunotherapy2

Real-world clinical applications in immunotherapy monitoring

Learn about Signatera in clinical practice from Dr. Andrew S. Poklepovic. In this on-demand webinar and Q&A, Dr. Poklepovic presents:
  • Key features that enable sensitive detection of ctDNA for molecular residual disease (MRD) monitoring
  • Clinical validation data in IO monitoring
  • Use in patients with melanoma in clinical practice
Dr. Andrew S. Poklepovic is an Associate Professor at VCU Medical Center and Medical Director at VCU Massey Cancer Center Clinical Trials Office and Dalton Ambulatory Oncology Center

Published data to inform clinical questions

Cutaneous Melanoma

Can Signatera help determine if a person is responding to immunotherapy or at risk for relapse?3

Uveal Melanoma*

Can Signatera help identify people who will have better overall outcomes during tebentafusp treatment?4

*This study used a non-commercially available custom Signatera panel

Merkel Cell Carcinoma

Can Signatera help identify people at higher risk for relapse, detect relapse early, and monitor treatment response?5

Interested in learning more about Signatera?

We look forward to hearing from you


1Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. 2020;1;873-881.

2BESPOKE study of ctDNA guided immunotherapy. identifier: NCT04761783. Updated September 17, 2021. Accessed April 5, 2022.

3Eroglu Z, et al. Circulating tumor DNA based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Presented at the 18th International Congress of the Society for Melanoma Research. October 28-31, 2021.

4Shoushtari AN, et al. 17570 Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patient. Ann. Oncol. 2021;32(5).

5Park SJ, et al. Circulating tumor DNA as a predictive biomarker in Merkel cell carcinoma. J. Am. Acad. Dermatol. 2022.